Qlife announced on 22 April that a research agreement had been made with Nordsjällands Hospital (NOH), for continued validation of the COVID-19 test.
Qlife has entered a first strategically important sales agreement for their COVID-19 test
The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga). The parties have developed a test protocol including the logistics for weekly testing.
“Our Sars-CoV-2 test is close to roll-out and this first commercial order is of great strategical importance to us. Sports is a perfect segment for Qlife, although in this specific pandemic time it is a challenging logistic task for us to offer this kind of mass testing. However, we feel that we can make a relatively large impact even with our limited production capacity, and Football is an important part of many peoples life - at Qlife we are happy that we can contribute to opening cultural life in Denmark in a safe way”, says Thomas Warthoe, CEO Qlife.
“We strongly believe that it is crucial to finish the season on course for all matches, but only if it can be done in a responsible way that does not strain the health care system. Some may think it sounds extreme with tests, but since physical contact on the course cannot be completely avoided, we take these precautions to avoid the spread of infection. " says Claus Thomsen, Director of Divisionsforeningen.
Qlife will collect test samples and run the tests with their licensed SIBA technology in-house on Egoo devices and, if needed, support in form of a multi-sample device in order to secure timely delivery. Alongside, Qlife will, within short be able to offer decentralized testing on the Egoo device at selected locations.
Since late March this year, Qlife has worked to introduce their Covid-19 test on the proprietary Egoo system and with the aim to deliver more decentral testing towards the segments of society that are not covered by public test offerings.
The aim for Qlife is to continue to decentralize and personalize clinical testing of specifically the Covid-19 test, but also other vira, bacteria and general biomarker tests that provides valuable health information at the right time. With the Egoo system as a front-line screening tool, quick results at the right time and place will make a significant difference.
Resolution on adoption of accounts and allocation of the company’s result
FINANCIAL SUMMARY FIRST QUARTER 2020
The parties have agreed a testing plan for all players, judges and club staff for Covid-19 in the professional leagues (3F SuperLiga and NordicBet Liga).
Qlife announces that it has entered into a research agreement with Nordsjællands Hospital (NOH), to continue the validation of the Egoo Sars-CoV-2 virus test.
Information regarding the coronavirus
Due to increased requests for information on route to market for Qlife’s COVID-19 test the company is updating the following:
Qlife announces that it has closed a license and supply agreement with Aidian Oy to access and incorporate their patented SIBA® Technology into the Egoo.Health platform.
Qlife went public on March 2 with a clear strategy for the next year, that strategy is still being followed and we do not see any large obstacles to it due to the Corona virus outbreak.